A Phase II Study of PCI-32765 in Patients with Relapsed and/or Refractory Multiple Myeloma

Full Title
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma
Disease Status

Bruton’s tyrosine kinase (btk) is an enzyme that cancer cells use to survive and grow. It has been implicated in the growth of multiple myeloma. In this study, researchers are assessing the safety and effectiveness of an investigational inhibitor of btk called PCI-32765 in patients with multiple myeloma that has returned or progressed despite prior therapy. This drug works differently than drugs currently approved for treating multiple myeloma.

PCI-32765 is a capsule that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma that has returned or progressed despite at least two prior regimens of therapy which included an immunomodulating drug (such as lenalidomide or thalidomide).
  • At least 3 weeks must have passed since completion of prior chemotherapy or radiation therapy and entry into the study.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Nikoletta Lendvai at 212-639-3368.

Hematology: Multiple Myeloma
Related Diseases